The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma. The U.S.

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis ...

The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...